Status:
COMPLETED
DHA Supplementation in Patients With STGD3
Lead Sponsor:
University of Utah
Conditions:
Dominantly Inherited Stargardt's Disease (STGD3)
Eligibility:
All Genders
18-105 years
Phase:
NA
Brief Summary
We have found that biomarkers of long-term elevated dietary intake of omega-3 fatty acids such as DHA and EPA are inversely associated with severity of disease phenotype in STGD3 patients. Therefore, ...
Eligibility Criteria
Inclusion
- All Moran Eye Center patients with STGD3
Exclusion
- All others
Key Trial Info
Start Date :
September 21 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 27 2017
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT00420602
Start Date
September 21 2007
End Date
December 27 2017
Last Update
May 9 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Moran Eye Center, University of Utah
Salt Lake City, Utah, United States, 84132